AACR annual meeting 2017
Tumor Treating Fields (TTFields)

PRECLINICAL

Evaluating the in-vitro effects of Tumor Treating Fields on T-cell responses. **G DIAMANT ET AL.**	617 / 21	Tumor Treating Fields decrease proliferation and clonogenicity of patient-derived WHO grade IV glioma cell lines. **SK MICHELHAUGH ET AL.**	3309 / 12
Effect of Tumor Treating Fields on cell proliferation and synergistic antitumor efficacy in combination with ionizing radiation. **E KIM ET AL.**	838 / 16	Cancer cells upregulate autophagy as a survival mechanism in response to Tumor Treating Fields (TTFields). **M GILADI ET AL.**	3315 / 18
Tumor Treating Fields (TTFields) affect human glioma cell migration, invasion and adherence properties in vitro. **D GARCIA-CARRACEDO ET AL.**	900 / 11	Tumor Treating Fields (TTFields) plus anti-PD-1 therapy induce immunogenic cell death resulting in enhanced antitumor efficacy. **M GILADI ET AL.**	3665 / 8
Tumor Treating Fields (TTFields) interfere with biological key properties of glioma cells in vitro. **M SILGINER ET AL.**	1504 / 19	Early metabolic response to Tumor Treating Fields in patients with recurrent glioblastoma. **S MITTAL ET AL.**	3730 / 15
Optimizing transducer array configuration for treatment of pancreatic cancer using Tumor Treating Fields (TTFields). **Z BOMZON ET AL.**	1569 / 18	A novel transducer array design optimizing TTFields delivery to the thorax. **HS HERSHKOVICH ET AL.**	4528 / 2
Using diffusion weighted imaging (DWI) data to accurately predict electric field delivery to the tumor during TTFields treatment. **C WENGER ET AL.**	4536 / 10	TTumor Treating Fields downregulate the BRCA1/FA pathway genes leading to reduced DNA repair capacity, the inhibition of mitophagy and enhanced cell death. **N KARANAM ET AL.**	2138 / 7
Feasibility study of a fractionation method in the treatment of Tumor Treating Fields. **Y JO ET AL.**	2312 / 6	The impact of microtubules on solution conductance and capacitance; implications for the use of AC electric fields in cancer therapy. **JA TUSZYNSKI ET AL.**	5228 / 8

For more information, e-mail **physicianinfo@novocure.com.**

novocure™

AACR annual meeting 2017
Tumor Treating Fields (TTFields)

CLINICAL

Tumor Treating Fields added to standard chemotherapy in newly diagnosed glioblastoma (GBM). Final results of a randomized, multi-center phase III trial. **R STUPP ET AL.** CT007	LUNAR: A phase 3 trial of TTFields in combination with PD-1 inhibitors or docetaxel for second line treatment of non-small cell lung cancer (NSCLC). **U WEINBERG ET AL.** CT071
Tumor Treating Fields in patients with glioblastomas: evaluation of treatment response using advanced MR imaging techniques. **S CHAWLA ET AL.** CT068	Modeling long term survival outcomes in glioblastoma patients treated with TTFields plus temozolomide and temozolomide monotherapy. **G GUZAUSKAS ET AL.** CT160
INNOVATE: A phase II study of TTFields (200 kHz) concomitant with weekly paclitaxel for recurrent ovarian carcinoma. **I VERGOTE ET AL.** CT135	PANOVA: A phase II study of TTFields (150 kHz) concomitant with standard chemotherapy for front-line therapy of advanced pancreatic adenocarcinoma.. **M BENEVIDES ET AL.** CT130
METIS: A phase 3 study of radiosurgery with TTFields for 1-10 brain metastases from NSCLC. **V GONDI ET A L.** CT161	Long term survival in glioblastoma patients after Tumor Treating Fields (TTFields) therapy. **AM RULSEH ET AL.** CT141
Rates and impact of combination immunotherapy with Tumor Treating Fields in a glioma cohort. **Y ODIA ET AL.** CT102	Tumor Treating Fields in pediatric high-grade glioma and ependymoma. **S GOLDMAN ET AL.** CT051

For more information, e-mail **physicianinfo@novocure.com.**

novocure™